Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortizatization of Intangibles (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Amortizatization of Intangibles for 13 consecutive years, with $89000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 63.97% year-over-year to $89000.0, compared with a TTM value of $739000.0 through Dec 2025, down 1.6%, and an annual FY2025 reading of $739000.0, down 1.6% over the prior year.
  • Amortizatization of Intangibles was $89000.0 for Q4 2025 at Heron Therapeutics, down from $130000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.0 million in Q4 2021 and bottomed at -$1.0 million in Q4 2023.
  • Average Amortizatization of Intangibles over 5 years is $157200.0, with a median of $251000.0 recorded in 2022.
  • Peak annual rise in Amortizatization of Intangibles hit 3181.82% in 2023, while the deepest fall reached 281.18% in 2023.
  • Year by year, Amortizatization of Intangibles stood at $1.0 million in 2021, then crashed by 43.06% to $574000.0 in 2022, then plummeted by 281.18% to -$1.0 million in 2023, then surged by 123.75% to $247000.0 in 2024, then tumbled by 63.97% to $89000.0 in 2025.
  • Business Quant data shows Amortizatization of Intangibles for HRTX at $89000.0 in Q4 2025, $130000.0 in Q3 2025, and $362000.0 in Q2 2025.